BONESUPPORT closed a round of funding for its CERAMENT platform.
The company is focused on injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery. Here are five things to know about the funding.
1. The company closed a $14 million round of funding.
2. The Scandinavian Pension Fund led the funding with a new investment.
3. The funds will be used to grow global sales and marketing and accelerated expansion of the CERAMENT platform.
4. The CERAMENT is a synthetic bone substitute designed to remodel into bone within six to 12 months and was the first CE-marked injectable gentamicin antibiotic eluting bone graft substitute indicated to promote and protect healing in osteomyelitis management.
5. The CERAMENT is used in emerging prosthetic infections, diabetic foot ulcers, war injuries, high-energy trauma and sports injuries.
"We are uniquely positioned to address an unmet clinical need and this additional funding will help us quickly expand our product offerings and accelerate market penetration," said BONESUPPORT CEO Lloyd Diamond.